Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Breast oncology · Invasive Ductal Carcinoma of the Breast

Standard of Care Treatment Strategies

At a Glance

Invasive ductal carcinoma is treated with a personalized combination of surgery, radiation, and medicines. The cancer’s hormone receptor, HER2, or triple-negative subtype helps determine whether treatment includes hormone therapy, HER2-targeted drugs, chemotherapy, or immunotherapy.

Treating Invasive Ductal Carcinoma (IDC)—or Invasive Breast Carcinoma of No Special Type (IBC-NST)—requires a coordinated team effort. Because this is the most common form of breast cancer, the “standard of care” is built on decades of research. Your plan will likely combine local treatments (to handle the cancer in the breast) and systemic treatments (to protect your whole body) [1][2].

The Sequence of Care: Neoadjuvant vs. Adjuvant

One of the first decisions is when to start systemic therapy (medication) [3]:

  • Neoadjuvant Therapy (Before Surgery): This is increasingly common, especially for HER2-positive and Triple-Negative (TNBC) subtypes [3]. It allows doctors to shrink the tumor (making surgery easier) and, more importantly, provides a “real-time test” to see if the cancer responds to the medicine [1]. If any cancer is left at the time of surgery (residual disease), your team may be able to switch to a different medicine for adjuvant therapy (for example, T-DM1 for HER2-positive disease, or capecitabine/olaparib for selected TNBC settings) to provide better protection [4][F004].
  • Adjuvant Therapy (After Surgery): This is the traditional approach, where the tumor is removed first, and then medication is given to kill any microscopic cells that might remain [5].

Local Therapy: Surgery and Radiation

Most patients have two main surgical options, which offer the same long-term survival rates for appropriate early-stage candidates [1][6]:

  1. Breast-Conserving Surgery (Lumpectomy): Only the tumor and a small “margin” of healthy tissue are removed [1]. This is almost always followed by radiation therapy to the remaining breast tissue to prevent the cancer from returning, though selected older, low-risk patients may safely omit radiation [7][8].
  2. Mastectomy: The entire breast is removed [1]. While mastectomy removes the breast tissue, it does not guarantee that radiation can be avoided. Radiation after mastectomy depends on T4 disease, tumor size, positive margins, nodal burden, biology, and neoadjuvant response.

Your team will also check your lymph nodes. A Sentinel Lymph Node Biopsy (SLNB) removes only the first few nodes to see if the cancer has spread [9]. An Axillary Lymph Node Dissection (ALND)—removing more nodes—is generally considered depending on the initial and residual nodal findings, neoadjuvant treatment, and applicable de-escalation criteria, not just a generic “higher nodal burden” [10][11].

Systemic Therapy: Tailored to Your Subtype

Medications are chosen based on the “fingerprint” of your cancer [5]:

Hormone Receptor-Positive (HR+/HER2-)

The foundation is Endocrine (Hormone) Therapy, usually taken for 5 to 10 years [5].

  • Aromatase Inhibitors (AIs): (e.g., Letrozole, Anastrozole) Standard for postmenopausal women; they block the body from making estrogen [12][13].
  • Tamoxifen: Often used for premenopausal women; it blocks the cancer cells’ ability to use estrogen [12].
  • Ovarian Function Suppression (OFS): For higher-risk premenopausal patients, doctors may use injections to temporarily “shut down” the ovaries [14][15].
  • CDK4/6 Inhibitors: (e.g., Abemaciclib or adjuvant Ribociclib) For those with a high risk of the cancer returning, adding this targeted pill to hormone therapy for a set duration can significantly reduce recurrence risk [16][17].

HER2-Positive

Treatment focuses on “blocking” the HER2 protein [18].

  • The Backbone: A combination of chemotherapy and Trastuzumab (Herceptin) [18][19].
  • Dual Blockade: For higher-risk cases, a second drug called Pertuzumab is added [20].
  • Post-Surgery Escalation: If cancer cells are still found at surgery, the medicine is often switched to T-DM1 (an “antibody-drug conjugate” that delivers chemo directly to HER2 cells) [4].

Triple-Negative (TNBC)

Since this subtype doesn’t have hormone or HER2 targets, chemotherapy is the primary systemic tool, alongside surgery and radiation [F004].

  • Immunotherapy: (e.g., Pembrolizumab) For selected high-risk early-stage TNBC, adding immunotherapy to chemotherapy before surgery and continuing it after surgery has become a standard approach to help the immune system fight the cancer [21][22].
Subtype Primary Strategy Common Medications
HR+/HER2- Block hormone signaling Tamoxifen, Letrozole, Abemaciclib
HER2+ Target HER2 protein Trastuzumab, Pertuzumab, T-DM1
TNBC Attack cells & boost immunity Chemotherapy, Pembrolizumab

Common questions in this guide

What is the difference between treatment before and after breast cancer surgery?
Treatment given before surgery is called neoadjuvant therapy; it can shrink the tumor and show how it responds to medicine. Treatment given after surgery is called adjuvant therapy; it aims to destroy tiny cancer cells that may remain. The best sequence depends on the cancer’s stage, subtype, and treatment goals.
Can I choose a lumpectomy instead of a mastectomy for invasive ductal carcinoma?
For appropriate people with early-stage invasive ductal carcinoma, lumpectomy followed by radiation and mastectomy offer similar long-term survival. Lumpectomy removes the tumor and a small margin of tissue, while mastectomy removes the breast. The choice depends on tumor features, radiation considerations, reconstruction options, and your preferences.
Will I need radiation after breast surgery?
Radiation is usually recommended after lumpectomy to lower the chance of cancer returning in the breast, although some older people with low-risk disease may be able to omit it. Radiation after mastectomy is not automatically unnecessary; it may be advised based on tumor size, spread to lymph nodes, margins, tumor biology, and response to pre-surgery treatment. Your treatment team will use these factors to make the recommendation.
How does my breast cancer subtype change the medicines I receive?
Medicine is selected according to whether the cancer has hormone receptors, excess HER2 protein, or neither. Hormone receptor-positive, HER2-negative cancer is commonly treated with long-term hormone-blocking medicine, while HER2-positive cancer may receive chemotherapy plus trastuzumab, with other HER2-blocking drugs for higher-risk disease. Triple-negative cancer is generally treated with chemotherapy, and selected high-risk cases may also receive pembrolizumab immunotherapy.
What happens if cancer remains after treatment before surgery?
If cancer remains in the breast or lymph nodes after medicine given before surgery, it is called residual disease. This result helps the team decide whether to change or add treatment after surgery. Examples include T-DM1 for some HER2-positive cancers and capecitabine or olaparib in selected triple-negative settings.
How are lymph node surgery options chosen for invasive ductal carcinoma?
A sentinel lymph node biopsy checks the first nearby underarm nodes most likely to receive cancer cells and removes only a few nodes. An axillary lymph node dissection removes more underarm nodes and is considered based on the initial and remaining node findings, pre-surgery treatment, and whether less extensive surgery is appropriate. Your surgeon can explain which approach fits your results.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my treatment plan following a 'neoadjuvant' (before surgery) or 'adjuvant' (after surgery) approach, and what are the advantages of that sequence for my specific subtype?
  2. 2.If we start with systemic therapy, how will we monitor the tumor's response before surgery?
  3. 3.Am I a candidate for breast-conserving surgery (lumpectomy), and if so, what type of radiation will I need afterward?
  4. 4.For my axillary (underarm) lymph nodes, are you planning a sentinel lymph node biopsy or an axillary dissection, and why?
  5. 5.Based on my subtype, which specific targeted therapies (like HER2-blockers, immunotherapy, or CDK4/6 inhibitors) are included in my plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Locoregional Therapy: From Mastectomy to Reconstruction, Targeted Surgery, and Ultra-Hypofractionated Radiotherapy.

    Banys-Paluchowski M, Hartmann S, Ditsch N, et al.

    Breast care (Basel, Switzerland) 2023; (18(6)):428-439 doi:10.1159/000533748.

    PMID: 38130814
  2. 2

    Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?

    Rosso KJ, Weiss A, Thompson AM

    Surgical oncology clinics of North America 2018; (27(1)):69-80 doi:10.1016/j.soc.2017.08.002.

    PMID: 29132566
  3. 3

    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

    Korde LA, Somerfield MR, Carey LA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

    PMID: 33507815
  4. 4

    Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

    von Minckwitz G, Huang CS, Mano MS, et al.

    The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.

    PMID: 30516102
  5. 5

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Caswell-Jin JL, Somerfield MR, Khan MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.

    PMID: 42647767
  6. 6

    Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2(-) breast cancers?

    Aktas A, Gunay-Gurleyik M, Aker F, et al.

    Cirugia y cirujanos 2023; (91(2)):186-194 doi:10.24875/CIRU.22000277.

    PMID: 37084295
  7. 7

    Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review.

    Speers C, Pierce LJ

    JAMA oncology 2016; (2(8)):1075-82 doi:10.1001/jamaoncol.2015.5805.

    PMID: 27243924
  8. 8

    Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.

    Smith BD, Bellon JR, Blitzblau R, et al.

    Practical radiation oncology 2018; (8(3)):145-152 doi:10.1016/j.prro.2018.01.012.

    PMID: 29545124
  9. 9

    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Park KU, Somerfield MR, Anne N, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(14)):1720-1741 doi:10.1200/JCO-25-00099.

    PMID: 40209128
  10. 10

    Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.

    Brackstone M, Baldassarre FG, Perera FE, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(27)):3056-3082 doi:10.1200/JCO.21.00934.

    PMID: 34279999
  11. 11

    Controversies in locoregional management of breast cancer with low volume pN0(i+) and pN1mi nodal disease.

    Dosani M, Truong PT

    Expert review of anticancer therapy 2019; (19(9)):803-810 doi:10.1080/14737140.2019.1660165.

    PMID: 31498712
  12. 12

    Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

    Lancet (London, England) 2015; (386(10001)):1341-1352 doi:10.1016/S0140-6736(15)61074-1.

    PMID: 26211827
  13. 13

    Current Endocrine Therapy in Hormone-Receptor-Positive Breast Cancer: From Tumor Biology to the Rationale for Therapeutic Tunning.

    Burciu OM, Merce AG, Cerbu S, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(7)) doi:10.3390/medicina61071280.

    PMID: 40731911
  14. 14

    Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

    Burstein HJ, Lacchetti C, Anderson H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(14)):1689-701 doi:10.1200/JCO.2015.65.9573.

    PMID: 26884586
  15. 15

    Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

    Regan MM, Francis PA, Pagani O, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(19)):2221-31 doi:10.1200/JCO.2015.64.3171.

    PMID: 27044936
  16. 16

    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

    Johnston SRD, Toi M, O'Shaughnessy J, et al.

    The Lancet. Oncology 2023; (24(1)):77-90 doi:10.1016/S1470-2045(22)00694-5.

    PMID: 36493792
  17. 17

    Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

    Johnston SRD, Harbeck N, Hegg R, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(34)):3987-3998 doi:10.1200/JCO.20.02514.

    PMID: 32954927
  18. 18

    Neoadjuvant treatment for HER2-positive breast cancer.

    Takada M, Toi M

    Chinese clinical oncology 2020; (9(3)):32 doi:10.21037/cco-20-123.

    PMID: 32527117
  19. 19

    Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.

    Harbeck N

    Breast (Edinburgh, Scotland) 2022; (62 Suppl 1()):S12-S16 doi:10.1016/j.breast.2022.01.006.

    PMID: 35148934
  20. 20

    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

    von Minckwitz G, Procter M, de Azambuja E, et al.

    The New England journal of medicine 2017; (377(2)):122-131 doi:10.1056/NEJMoa1703643.

    PMID: 28581356
  21. 21

    Role of immunotherapy in early breast cancer: past, present, and future.

    Britten K, Bardia A, McAndrew N

    Targeted oncology 2025; (20(4)):615-625 doi:10.1007/s11523-025-01157-1.

    PMID: 40540147
  22. 22

    Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.

    Mohamed A, Kruse M, Tran J

    Expert review of anticancer therapy 2023; (23(10)):1071-1084 doi:10.1080/14737140.2023.2262764.

    PMID: 37747062

This page is for informational purposes only and does not constitute medical advice. Your breast cancer team can tailor treatment sequence, surgery, radiation, and medicines to your subtype, stage, response, and preferences.

Get notified when new evidence is published on breast ductal adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.